grant
Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes
Organization UNIVERSITY OF TEXAS HLTH SCIENCE CENTERLocation SAN ANTONIO, UNITED STATESPosted 21 Sept 2012Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2026Active Follow-upAdipocytesAdipose CellAdult-Onset Diabetes MellitusAgonistApplications GrantsBenchmarkingBest Practice AnalysisBeta CellBody Weight decreasedBody fatBone DensityBone Mineral DensityCausalityCell FunctionCell PhysiologyCell ProcessCellular FunctionCellular PhysiologyCellular ProcessChemosensitizationChemosensitization/PotentiationClinicalCombined Modality TherapyComplexD-GlucoseDataDefectDevelopmentDextroseDiabetes MellitusDimethylbiguanidineDimethylguanylguanidineDrugsEtiologyEx4 peptideExendin 4FailureFat CellsFatsFatty acid glycerol estersGIP receptorGLP-1GLP-1 RAGLP-1 agonistGLP-1 analogGLP-1 receptor agonistGlimepirideGlp-1Glucagon like peptide 1 agonistGlucagon like peptide-1 receptor agonistsGlucagon-like peptide-1 analogGlucoseGlucose Plasma ConcentrationGlucose-Dependent Insulinotropic PolypeptideGlycohemoglobin AGlycosylated hemoglobin AGoalsGrant ProposalsHb A1Hb A1a+bHb A1cHbA1HbA1cHemoglobin A(1)Humulin RHyperglycemiaInsulinInsulin CellInsulin Secreting CellKetosis-Resistant Diabetes MellitusKidneyKidney DiseasesKidney Urinary SystemLipocytesLiverMature LipocyteMature fat cellMaturity-Onset Diabetes MellitusMeasurementMeasuresMedicationMetabolicMetforminMethodsMicrovascular DysfunctionMultimodal TherapyMultimodal TreatmentMuscleMuscle TissueMyocardialN,N-dimethyl-imidodicarbonimidic diamideNIDDMNephropathyNewly DiagnosedNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusNovolin ROutcome StudyPatientsPharmaceutical PreparationsPioglitazonePost-MenopausePost-menopausal PeriodPostmenopausal PeriodPostmenopausePotentiationRandomizedReceptor GeneRecommendationRegimenRegular InsulinRenal DiseaseRiskRisk ReductionRoleSkeletal MuscleSlow-Onset Diabetes MellitusStable Diabetes MellitusSubcellular ProcessSulfonylurea CompoundsT2 DMT2DT2DMTestingTherapeuticTimeType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesVoluntary MuscleWeight GainWeight IncreaseWeight LossWeight ReductionWomanactive followupadult onset diabetesafter menopausebenchmarkblood glucose regulationbody weight gainbody weight increasebody weight losscausationcombination therapycombined modality treatmentcombined treatmentcomparable efficacycomparative effectivenesscomparative effectiveness studycomparative efficacycompare efficacyconventional therapyconventional treatmentdetermine efficacydevelopmentaldiabetesdiabetic patientdisease causationdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy studyefficacy testingevaluate efficacyexamine efficacyexenatidefollow upfollow-upfollowed upfollowing menopausefollowupgastric inhibitory polypeptide receptorglargineglucagon-like peptide 1glucose controlglucose homeostasisglucose regulationglucose-dependent insulinotropic polypeptide receptorhemoglobin A1chepatic body systemhepatic organ systemhyperglycemicimprovedinsulin secretioninsulin sensitivityintervention algorithmketosis resistant diabeteskidney disorderliraglutidematurity onset diabetesmicrovascular complicationsmicrovascular diseasemulti-modal therapymulti-modal treatmentmuscularpast menopausepost-menopausalpostmenopausalpostmenopausal statuspreventpreventingprimary outcomeprotective effectrandomisationrandomizationrandomly assignedrecruitreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrenalrenal disorderrisk-reducingsecondary outcomesmall vessel diseasesocial rolestandard of caresulfonylureatherapeutic algorithmtherapy algorithmtreatment algorithmtype 2 DMtype II DMtype two diabeteswt gainwt-lossβ-cellβ-cellsβCell
Description preview
Project Summary/Abstract
The current ADA/EASD recommendation for glucose control in newly diagnosed T2DM patients
who are free from CVD and renal disease is to start on metformin and sequentially add other
glucose lowering agents upon metformin failure to maintain HbA1c <7.0%. The recently
completed GRADE study, which had tested the efficacy of 4…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click